All companies
CSL Limited logo

What smart money is saying about CSL LimitedAustralia flag

CSL.AX · Healthcare · Biotechnology · Market cap $59.77B

2 funds in our archive have pitched CSL Limited — most recently Brown Advisory Global Value Select Strategy in June 2026.

Company profile

CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.

Fund coverage · 2 theses

  • Brown Advisory Global Value Select Strategy
    June 2026

    CSL Limited is a high-quality biopharma business with attractive economics now available at a low multiple.

    Read the full thesis
  • Cooper Investors Endowment Fund
    December 2024

    CSL Ltd is a company with a strong growth outlook despite recent setbacks in its clinical pipeline, driven by robust product offerings and a shift in management focus toward capital returns.

    Read the full thesis

Read every full thesis on CSL Limited

Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans